(CercleFinance.com) – Biosynex announces that it has taken a stake
75% majority shareholder in Medkoncept AS, a company located near Copenhagen, Denmark.
Founded in 2017, Medkoncept was notably the exclusive distributor in
Denmark of rapid diagnostic tests related to Covid-19.
Medkoncept, which will soon become Biosynex Nordic, has in fact marketed on behalf of Biosynex more than 26 million antigenic tests on the Danish market since 2021.
With this new majority acquisition outside France, Biosynex intends to accelerate penetration of the Nordic market in Denmark and Norway initially before rolling out in Sweden and Finland in 2023 thanks to multiple synergy effects.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
